腫瘤

RPS6KB1過表達預測原發性肝細胞癌患者預後較差

作者:Pin Dong Li等 來源:Medical Oncology 日期:2012-06-18
導讀

RPS6KB1過表達預測原發性肝細胞癌患者預後較差

Overexpression of RPS6KB1 predicts worse prognosis in primary HCC patients

關鍵字: RPS6KB1 | 肝細胞癌

RPS6KB1過表達預測原發性肝細胞癌患者預後較差

Overexpression of RPS6KB1 predicts worse prognosis in primary HCC patients
Abstract
RPS6KB1 (ribosomal protein S6 kinase, 70 kDa, polypeptide 1) plays a key role in regulating protein translation. The role of RPS6KB1 in HCC (hepatocellular carcinoma) has not been fully investigated. This study was undertaken to determine the clinicopathological features and prognostic value of RPS6KB1 in HCC. We examined RPS6KB1 expression in 30 paired liver cancer tissues and adjacent noncancerous tissues by reverse transcription real-time PCR and Western blotting. In addition, we analyzed RPS6KB1 expression in 87 HCC samples by immunohistochemistry. The expression of RPS6KB1 was significantly increased in cancer tissues. Clinicopathological analysis showed that the expression of RPS6KB1 was significantly correlated with tumor size, histopathologic classifications, and serum alpha-fetoprotein (AFP). Kaplan–Meier survival curves revealed that increased expression of RPS6KB1 correlated with poor prognosis of HCC patients. RPS6KB1 expression was an independent prognostic marker for overall survival of HCC patients by multivariate analysis. Our data suggest that RPS6KB1 may play an important role in the progression of HCC and could serve as a potential molecular target for HCC therapy.
原文鏈接:http://www.springerlink.com/content/wl1v5674k331ll21/

分享:

相關文章

    評論

    我要跟帖
    發表
    回複 小鴨梨
    發表

    copyright©醫學論壇網 版權所有,未經許可不得複製、轉載或鏡像

    京ICP證120392號 京公網安備110105007198 京ICP備10215607號-1 (京)網藥械信息備字(2022)第00160號
    //站內統計//百度統計//穀歌統計//站長統計
    *我要反饋: 姓 名: 郵 箱: